Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.

Mulvenna, P; Nankivell, M; Barton, R; Faivre-Finn, Corinne; Wilson, P; McColl, E; Moore, B; Brisbane, I; Ardron, D; Holt, T; Morgan, S; Lee, C; Waite, K; Bayman, Neil A; Pugh, C; Sydes, B; Stephens, R; Parmar, M; Langley, R

Affiliation

Northern Centre for Cancer Care, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Issue Date

2016-09-02

Metadata

Show full item record

Abstract

Whole brain radiotherapy (WBRT) and dexamethasone are widely used to treat brain metastases from non-small cell lung cancer (NSCLC), although there have been no randomised clinical trials showing that WBRT improves either quality of life or overall survival. Even after treatment with WBRT, the prognosis of this patient group is poor. We aimed to establish whether WBRT could be omitted without a significant effect on survival or quality of life.

Citation

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. 2016, Lancet

Journal

Lancet

URI

http://hdl.handle.net/10541/619970

DOI

10.1016/S0140-6736(16)30825-X

PubMed ID

27604504

Type

Article

Language

ISSN

1474-547X

Collections

All Christie Publications